Median progression-free survival (PFS) in pancreatic neuroendocrine tumor (P-NET) patients was 24.5 months on 177Lu-edotreotide arm vs. 14.7 months on everolimus armObjective response rate (ORR) was h ...
Jodie Gallagher, Head of UK IFA Products at FE fundinfo, looks at how AI is being used to strengthen the operational backbone ...
British number one Emma Raducanu says she wants to "bring my instincts back out" as she prepares for Indian Wells in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results